Search results for "leukemia"

showing 10 items of 976 documents

Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

2014

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy and the fifth most common type of cancer in more developed regions of the world (1). Numerous NHL subtypes with distinct combinations of morphologic, immunophenotypic, genetic, and clinical features are currently recognized (2,3). The incidence of NHL subtypes varies substantially by age, sex, and race/ethnicity (4–7). However, the etiological implications of this biological, clinical, and epidemiological diversity are incompletely understood. The importance of investigating etiology by NHL subtype is clearly supported by research on immunosuppression, infections, and autoimmune diseases, which are the strongest and most e…

AdultMaleCancer ResearchAdolescentChronic lymphocytic leukemiaFollicular lymphomaComorbidityDiseaseNon-Hodgkin lymphoma (NHL)ArticleYoung AdultRisk Factorsimmune system diseasesOccupational Exposurehemic and lymphatic diseasesOdds RatiomedicineCluster AnalysisHumansRisk factorFamily historyLife StyleAgedAged 80 and overInternational Lymphoma Epidemiology Consortium (InterLymph)business.industryLymphoma Non-HodgkinAustraliaCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLymphomaEuropeOncologyCase-Control StudiesNorth AmericaImmunologyFemalebusinessJNCI Monographs
researchProduct

Is the risk of childhood leukaemia associated with socioeconomic measures in Denmark? A nationwide register‐based case‐control study

2021

The aetiology of childhood leukaemia is poorly understood. Knowledge about differences in risk by socioeconomic status (SES) may enhance etiologic insights. We conducted a nationwide register-based case-control study to evaluate socioeconomic differences in the risk of childhood leukaemia in Denmark and to access whether associations varied by different measures of SES, time point of assessment, leukaemia type and age at diagnosis. We identified all cases of leukaemia in children aged 0 to 19 years, born and diagnosed between 1980 and 2013 from the Danish Cancer Registry (N = 1336) and sampled four individually matched controls per case (N = 5330). We used conditional logistic regression mo…

AdultMaleCancer ResearchAdolescentOffspringDenmark610 Medizinsocioeconomic factorsDiseasesocioeconomic statusDanishYoung Adult03 medical and health sciencesmyeloid leukaemia0302 clinical medicinechildhood leukaemiaRisk Factors610 Medical scienceschildhood cancerHumansMedicineRegistriesChildSocioeconomic statusbusiness.industryInfant NewbornCase-control studyInfantOdds ratiolymphoid leukaemiaConfidence intervallanguage.human_languageregister-based studyCancer registryLeukemia Myeloid AcuteSocial ClassOncologyCase-Control StudiesChild Preschool030220 oncology & carcinogenesislanguageFemalebusinessDemographyInternational Journal of Cancer
researchProduct

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acut…

2013

Unlike cytarabine, cellular entry of Elacytarabine, the elaidic acid ester derivative of cytarabine, is independent of the human equilibrative nucleoside transporter 1 (hENT1). This phase II study tested whether the hENT1 blast expression level can be used as a predictive marker for cytarabine response and if the efficacy of elacytarabine is independent of hENT1 expression. A total of 51 patients with acute myeloid leukemia (AML) induction failure were given elacytarabine-idarubicin as a second induction course. The hENT1 expression level was analyzed prior to first induction and/or prior to treatment with elacytarabine. The overall response rate (ORR) was 41% and the safety profile was man…

AdultMaleCancer ResearchAdolescentPhases of clinical researchGene ExpressionPharmacologyNucleoside transporterEquilibrative nucleoside transporter 1Equilibrative Nucleoside Transporter 1Young AdultBone MarrowAntineoplastic Combined Chemotherapy ProtocolsmedicineIdarubicinHumansAgedPredictive markerbiologyElacytarabinebusiness.industryCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyInduction ChemotherapyMiddle AgedLeukemia Myeloid AcuteTreatment OutcomeOncologybiology.proteinCytarabineFemalebusinessIdarubicinmedicine.drugLeukemialymphoma
researchProduct

Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups

2009

B cell chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder with a variable clinical course. Patients with unmutated IgV(H) gene show a shorter progression-free and overall survival than patients with immunoglobulin heavy chain variable regions (IgV(H)) gene mutated. In addition, BCL6 mutations identify a subgroup of patients with high risk of progression. Gene expression was analysed in 36 early-stage patients using high-density microarrays. Around 150 genes differentially expressed were found according to IgV(H) mutations, whereas no difference was found according to BCL6 mutations. Functional profiling methods allowed us to distinguish KEGG and gene ontology terms showing…

AdultMaleCancer ResearchBCL6BiologyIgVHgenomichemic and lymphatic diseasesmedicineHumansKEGGGenemicroarraysAgedAged 80 and overRegulation of gene expressionGeneticsB-LymphocytesGene Expression ProfilingZAP70HematologyMiddle Agedmedicine.diseaseBCL6Leukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsGene Expression Regulation NeoplasticGene expression profilingLeukemiaOncologyTranscriptomicHealthMutationProto-Oncogene Proteins c-bcl-6Cancer researchImmunoglobulin heavy chainFemaleImmunoglobulin Heavy ChainsCLL
researchProduct

Variant Three-Way Translocation of Inversion 16 in AML-M4Eo Confirmed by Fluorescence In Situ Hybridization Analysis

1999

The inv(16) and t(16;16) characterize a subgroup of acute myelomonocytic leukemia (AML) with distinct morphological features and a favorable prognosis. Both cytogenetic abnormalities result in a fusion of CBF beta at 16q22 and MYH11 gene at 16p13, whose detection by PCR and fluorescence in situ hybridization (FISH) is useful for diagnosis and monitoring of the disease. Variant translocations of inv(16)/t(16;16) are very rare and whether they are also associated with a favorable prognosis is unknown. We report a patient presenting with typical AML-M4Eo and a three-way translocation of inv(16) involving 16p13, 16q22, and 3q22. FISH studies on bone marrow (BM) chromosomes using CBFB and MYH11 …

AdultMaleCancer ResearchChromosomal translocationBiologyLeukemia Myelomonocytic AcuteTranslocation GeneticChromosome 16GeneticsmedicineHumansMolecular BiologyIn Situ Hybridization FluorescenceChromosomal inversionmedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionHybridization probemedicine.diseaseMolecular biologyEosinophilsLeukemiaFusion transcriptChromosome InversionAcute myelomonocytic leukemiaFemaleChromosomes Human Pair 16Fluorescence in situ hybridizationCancer Genetics and Cytogenetics
researchProduct

Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.

2008

Therapeutic effects of haematopoietic stem cell transplantation are not limited to maximal chemoradiotherapy and subsequent bone marrow regeneration, but include specific as well as unspecific immune reactions known as graft-versus-leukaemia (GvL) effects. Specific immune reactions are likely to be particularly relevant to the long-term treatment of diseases, such as chronic myeloid leukaemia (CML), in which residual cells may remain quiescent and unresponsive to cytotoxic and molecular therapies for long periods of time. Specific GvL effects result from the expression on leukaemic cells of specific tumour-associated antigens (TAAs) in the context of HLA proteins. As human leukocyte antigen…

AdultMaleCancer ResearchDNA ComplementaryT-LymphocytesAntigen-Presenting CellsEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenBiologyAntigenhemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCytotoxic T cellHumansIn Situ Hybridization FluorescenceReverse Transcriptase Polymerase Chain ReactionHematologyNM23 Nucleoside Diphosphate Kinasesmedicine.diseaseTransplantationHaematopoiesismedicine.anatomical_structureOncologyImmunologyBone marrowStem cellChronic myelogenous leukemiaLeukemia
researchProduct

The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3…

2008

Activating mutations of FLT3 are found in approximately one-third of acute myeloid leukemia (AML)-cases and are considered to represent an attractive therapeutic target. In this study, we report that the hydroxystyryl-acrylonitrile compound LS104 inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells in vitro. Immunoblot and phosphoprotein-FACS analysis demonstrated inhibiton of phosphorylation of FLT3-ITD and of its downstream targets. In pharmacokinetic studies, a rapid and dose dependent cellular uptake of LS104 lasting up to 11h could be demonstrated. Combination of LS104 with chemotherapeutic agents markedly enhanced cytotoxic effects. Recently, a…

AdultMaleCancer ResearchDaunorubicinmedicine.drug_classBlotting WesternFluorescent Antibody TechniqueApoptosisPharmacologyReceptor tyrosine kinaseTyrosine-kinase inhibitorStyrenesColony-Forming Units AssayMiceBone Marrowhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor Cells CulturedCD135AnimalsHumansPoint MutationTissue DistributionAgedCell ProliferationAged 80 and overbiologyAcrylonitrileDaunorubicinCytarabineMyeloid leukemiaCell DifferentiationHematologyMiddle Agedmedicine.diseaseLeukemiaLeukemia Myeloid AcuteOncologyfms-Like Tyrosine Kinase 3Fms-Like Tyrosine Kinase 3Cytarabinebiology.proteinCancer researchDrug Therapy CombinationFemalemedicine.drugSignal TransductionLeukemia research
researchProduct

Pneumonia in Febrile Neutropenic Patients and in Bone Marrow and Blood Stem-Cell Transplant Recipients: Use of High-Resolution Computed Tomography

1999

PURPOSE: To obtain statistical data on the use of high-resolution computed tomography (HRCT) for early detection of pneumonia in febrile neutropenic patients with unknown focus of infection. MATERIALS AND METHODS: One hundred eighty-eight HRCT studies were performed prospectively in 112 neutropenic patients with fever of unknown origin persisting for more than 48 hours despite empiric antibiotic treatment. Fifty-four of these studies were performed in transplant recipients. All patients had normal chest roentgenograms. If pneumonia was detected by HRCT, guided bronchoalveolar lavage was recommended. Evidence of pneumonia on chest roentgenograms during follow-up and micro-organisms detected…

AdultMaleCancer ResearchHigh-resolution computed tomographymedicine.medical_specialtyNeutropeniamedicine.medical_treatmentHematopoietic stem cell transplantationNeutropeniaFever of Unknown OriginPredictive Value of TestsmedicineHumansProspective StudiesFever of unknown originLungAgedBone Marrow TransplantationAged 80 and overmedicine.diagnostic_testbusiness.industryRespiratory diseaseHematopoietic Stem Cell TransplantationPneumoniaMiddle Agedrespiratory systemmedicine.diseaserespiratory tract diseasesSurgeryLeukemia Myeloid AcutePneumoniaBronchoalveolar lavageOncologyFemaleRadiologyTomography X-Ray ComputedComplicationbusinessBronchoalveolar Lavage FluidAlgorithmsJournal of Clinical Oncology
researchProduct

miR-155 regulative network in FLT3 mutated acute myeloid leukemia

2015

Abstract Background Acute myeloid leukemia (AML) represents a heterogeneous disorder with recurrent chromosomal alterations and molecular abnormalities. Among AML with normal karyotype (NK-AML) FLT3 activating mutation, internal tandem duplication (FLT3-ITD), is present in about 30% of patients, conferring unfavorable outcome. Our previous data demonstrated specific up-regulation of miR-155 in FLT3-ITD+ AML. miR-155 is known to be directly implicated in normal hematopoiesis and in some pathologies such as myeloid hyperplasia and acute lymphoblastic leukemia. Methods and results To investigate about the potential influence of miR-155 de-regulation in FLT3-mutated AML we generated a transcrip…

AdultMaleCancer ResearchMyeloidJUNBNetworkBiologyYoung Adultchemistry.chemical_compoundAMLhemic and lymphatic diseasesmicroRNACEBPBmedicineHumansGene silencingGene Regulatory NetworksAML; MicroRNA; NetworkAgedAged 80 and overGene Expression Regulation LeukemicGene Expression ProfilingMyeloid leukemiaMicroRNAHematologyMiddle AgedLeukemia Myeloid AcuteMicroRNAsmedicine.anatomical_structurefms-Like Tyrosine Kinase 3OncologyRUNX1chemistryMutationCancer researchFemaleMyelopoiesisK562 Cells
researchProduct

Identification and molecular characterization of CALM/AF10fusion products in T cell acute lymphoblastic leukemia and acute myeloid leukemia

2000

The t(10;11)(p12-p13;q14-q21) observed in a subset of patients with either acute lymphoblastic leukemia or acute myeloid leukemia has been shown to result in the fusion of AF10 on chromosome 10 with CALM (also named CLTH) on chromosome 11. AF10 was originally identified as a fusion partner of MLL in the t(10;11)(p12-p13;q23) observed in myeloid leukemia. CALM is a newly isolated gene, cloned as the fusion partner of AF10 in the monocytoid cell line, U937. In order to understand the relationship between MLL, AF10, CALM and the leukemic process, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction were used to study a series of nine leukemia patients with a t…

AdultMaleCancer ResearchMyeloidOncogene Proteins FusionChromosomal translocationBiologyImmunophenotypingImmunophenotypinghemic and lymphatic diseasesAcute lymphocytic leukemiamedicineHumansCloning MolecularChildneoplasmsIn Situ Hybridization FluorescenceDNA PrimersABLBase Sequencemedicine.diagnostic_testReverse Transcriptase Polymerase Chain ReactionMyeloid leukemiaHematologyMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseVirologyLeukemiamedicine.anatomical_structureOncologyLeukemia MyeloidAcute DiseaseCancer researchFluorescence in situ hybridizationLeukemia
researchProduct